[HTML][HTML] Targeting the STAT3 oncogenic pathway: Cancer immunotherapy and drug repurposing
Y Dong, J Chen, Y Chen, S Liu - Biomedicine & Pharmacotherapy, 2023 - Elsevier
Immune effector cells in the microenvironment tend to be depleted or remodeled, unable to
perform normal functions, and even promote the malignant characterization of tumors …
perform normal functions, and even promote the malignant characterization of tumors …
Chronic inflammatory demyelinating Polyradiculoneuropathy: current therapeutic approaches and future outlooks
YA Rajabally - ImmunoTargets and Therapy, 2024 - Taylor & Francis
Chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) is a treatable
autoimmune disorder, for which different treatment options are available. Current first-line …
autoimmune disorder, for which different treatment options are available. Current first-line …
Pharmacokinetics, pharmacodynamics, safety, and tolerability of a single-dose riliprubart, an anti-C1s humanized monoclonal antibody in East-Asian Adults: results …
Y Li, J Young Na, Y Zhu, J Oh, A Zhao… - Expert Opinion on …, 2024 - Taylor & Francis
ABSTRACT Objectives This Phase 1 trial was planned toinvestigate the pharmacokinetics
(PK), pharmacodynamics (PD), safety, andtolerability of a single dose of riliprubart in healthy …
(PK), pharmacodynamics (PD), safety, andtolerability of a single dose of riliprubart in healthy …
Prevalence, Clinical Profiles, and Prognosis of CIDP in Japanese Nationwide Survey: Analyses of 1,257 Diagnosis-Confirmed Patients
Y Aotsuka, S Misawa, T Suichi, K Shibuya… - Neurology, 2024 - AAN Enterprises
Background and Objectives To investigate the current epidemiology, clinical profile, and
treatment of chronic inflammatory demyelinating polyneuropathy (CIDP) using a nationwide …
treatment of chronic inflammatory demyelinating polyneuropathy (CIDP) using a nationwide …
免疫介在性ニューロパチーの新規治療展望
桑原基 - 臨床神経学, 2024 - jstage.jst.go.jp
要旨 免疫介在性ニューロパチーでは副腎皮質ステロイド, 血漿浄化療法, 経静脈的免疫グロブリン
療法が長らく治療の中心となっている. しかしながら, これらの治療においても治療抵抗例が一定数 …
療法が長らく治療の中心となっている. しかしながら, これらの治療においても治療抵抗例が一定数 …